2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldose Reductase

Aldose Reductase

Aldose Reductase

Related Products

PDF 0.43 MB

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-105185R
    Fidarestat (Standard)
    		Inhibitor
    Fidarestat (Standard) is the analytical standard of Fidarestat (HY-105185). This product is intended for research and analytical applications. Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
    Fidarestat (Standard)
  • HY-106198R
    Lidorestat (Standard)
    		Inhibitor
    Lidorestat (Standard) is the analytical standard of Lidorestat (HY-106198). This product is intended for research and analytical applications. Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.
    Lidorestat (Standard)
  • HY-B1202R
    Alrestatin (Standard)
    		Inhibitor
    Alrestatin (AY-22284) Standard is the analytical standard of Alrestatin (HY-B1202). This product is intended for research and analytical applications. Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases.
    Alrestatin (Standard)
  • HY-176164
    ALR2-IN-6
    		Inhibitor
    ALR2-IN-6 (compound 9) is a potent and competitive ALR2 inhibitor with a Ki of 0.064 μM. ALR2-IN-6 can be used in the study of neuropathy, retinopathy, and nephropathy.
    ALR2-IN-6
  • HY-129685
    M79175
    		Inhibitor
    M79175 is an aldose reductase inhibitor that can be used in the study of early diabetic retinopathy.
    M79175
  • HY-N0310R
    Soyasaponin Bb (Standard)
    		Inhibitor
    Soyasaponin Bb (Standard) is the analytical standard of Soyasaponin Bb (HY-N0310). This product is intended for research and analytical applications. Soyasaponin Bb is an orally active, covalent inducer of heme oxygenase HO-1 and an inhibitor of aldose reductase AKR1B1. Soyasaponin Bb can regulate oxidative stress pathways, enhance antioxidant capacity, reduce reactive oxygen species (ROS) generation, and inhibit lipid peroxidation and hepatocyte apoptosis. Soyasaponin Bb improves alcohol-induced hepatocyte membrane damage and liver function abnormalities, and improves Scopolamine (HY-N0296)-induced memory impairment. Soyasaponin Bb has antioxidant, hepatoprotective, and neuroprotective activities.
    Soyasaponin Bb (Standard)
  • HY-B1392A
    Esmolol
    		Inhibitor
    Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol attenuates post resuscitation myocardial dysfunction. Esmolol improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers.
    Esmolol
  • HY-162758
    ALR2-IN-5
    		Inhibitor
    ALR2-IN-5 (Compound 10a) is an inhibitor of ALR2 with an IC50 value of 99.29 nM. ALR2-IN-5 exhibits hypoglycemic effects and can be utilized in research related to diabetes.
    ALR2-IN-5
  • HY-W014242
    2-(2-Chlorobenzamido)acetic acid
    		Inhibitor
    2-(2-Chlorobenzamido)acetic acid is an aldose reductase inhibitor with an IC50 of 31 μM. 2-(2-Chlorobenzamido)acetic acid can be used for the research of chronic diabetes.
    2-(2-Chlorobenzamido)acetic acid
  • HY-183855
    WF-2421
    		Inhibitor
    WF-2421 is an aldose reductase inhibitor with an IC50 of 0.03 μM against rabbit-derived aldose reductase. WF-2421 acts as a non-competitive inhibitor of aldose reductase using dl-glyceraldehyde as the substrate. WF-2421 can be used in the research of diabetic complications (cataract, neuropathy, retinopathy, nephropathy).
    WF-2421
  • HY-N0102R
    Isoliquiritigenin (Standard)
    		Inhibitor
    Isoliquiritigenin (Standard) is the analytical standard of Isoliquiritigenin. This product is intended for research and analytical applications. Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
    Isoliquiritigenin (Standard)
  • HY-161472
    Aldose reductase-IN-7
    		Inhibitor
    Aldose reductase-IN-7 (Compound 6k) targets Aldose reductase. Aldose reductase-IN-7 exhibits potent enzyme inhibitory activity (Ki = 0.186 ± 0.020 μM), showing superiority to Epalrestat (HY-66009), which is currently in clinical use. Aldose reductase-IN-7 is less cytotoxic and possesses potent anticancer activity.
    Aldose reductase-IN-7
  • HY-106697R
    Ponalrestat (Standard)
    		Inhibitor
    Ponalrestat (Standard) (ICI 128436 (Standard)) is the analytical standard of Ponalrestat (HY-106697). This product is intended for research and analytical applications. Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol.
    Ponalrestat (Standard)
  • HY-116600
    AL-4114
    		Inhibitor
    AL-4114 is an aldose reductase inhibitor which can be utilized in research related to the prevention of diabetic cataractogenesis.
    AL-4114
  • HY-119842
    ALO1567
    		Inhibitor
    ALO1567 (AL1567) is an orally available aldose reductase inhibitor with an IC50 of 27 nM for rat lens aldose reductase. ALO1567 can be used in the research of diabetes.
    ALO1567
  • HY-W715538
    Rhetsinine
    		Inhibitor
    Rhetsinine is an aldose reductase inhibitor isolated from Evodia rutaecarpa, exhibiting an IC50 value of 24.1 μM. At a concentration of 100 μM, rhetsinine significantly inhibits sorbitol accumulation by 79.3%. This compound shows potential for research in diabetic complications, including diabetic neuropathy and retinopathy.
    Rhetsinine
  • HY-124432
    CRT0093964
    		Inhibitor
    CRT0093964 is an isoform-selective non-carboxylate inhibitor of AKR1C3 (IC50=0.11 μM) with no activity against AKR1C1, AKR1C2, AKR1C4, COX-1, and COX-2.CRT0093964 can be used for the research of leukemia, hormone-related cancers, colon cancer.
    CRT0093964
  • HY-W653944
    Epalrestat-d5
    		Inhibitor
    Epalrestat-d5 is deuterium labeled Epalrestat. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.
    Epalrestat-d<sub>5</sub>
  • HY-N14450
    Salfredin A7
    		Inhibitor
    Salfredin A7 is an aldose reductase inhibitor.
    Salfredin A7
Cat. No. Product Name / Synonyms Application Reactivity